| Literature DB >> 32753859 |
Giovanni Iolascon1, Alessandro de Sire1,2,3, Dario Calafiore1,4, Maria Grazia Benedetti5, Carlo Cisari2,6, Giulia Letizia Mauro7, Silvia Migliaccio8, Ranuccio Nuti9, Giuseppina Resmini10, Stefano Gonnelli9, Antimo Moretti1.
Abstract
OBJECTIVE: To assess physical performance, number of falls, previous fragility fractures, and ongoing pharmacological therapy in a cohort of post-menopausal women, according to their risk of falling.Entities:
Keywords: accidental falls; bone; fractures; osteoporosis; rehabilitation; walking speed
Mesh:
Substances:
Year: 2020 PMID: 32753859 PMCID: PMC7354000 DOI: 10.2147/CIA.S257304
Source DB: PubMed Journal: Clin Interv Aging ISSN: 1176-9092 Impact factor: 4.458
Differences in Outcome Measures Among Groups in the Study Population (n=753)
| At Low Risk of Falling | At Moderate Risk of Falling | At High Risk of Falling | ||
|---|---|---|---|---|
| 4MGS (m/s) | 0.89 ± 0.34 | 0.57 ± 0.38 | 0.37 ± 0.20 | <0.001** |
| 4MGS ≤ 0.8 m/s | 152 (40.21) | 172 (69.64) | 120 (93.75) | <0.001* |
| UST (s) | 15.70 ± 15.04 | 8.39 ± 10.37 | 3.17 ± 2.87 | <0.001** |
| Pathological UST | 290 (76.72) | 224 (90.69) | 127 (99.22) | <0.001* |
| Falls in the previous year | ||||
| 0 | 322 (85.19) | 58 (23.48) | 0 (0.00) | <0.001* |
| 1 | 52 (13.76) | 107 (43.32) | 61 (47.66) | <0.001* |
| ≥2 | 4 (1.06) | 82 (33.20) | 67 (52.34) | <0.001* |
| Vertebral fragility fractures | 42 (11.11) | 65 (26.32) | 67 (52.34) | <0.001* |
| Hip fragility fractures | 6 (1.59) | 25 (10.12) | 36 (28.13) | <0.001* |
| NVNH fractures | 19 (5.03) | 14 (5.67) | 14 (10.94) | <0.001* |
Notes: Values are expressed as mean ± standard deviation for continuous data and counts (percentages) for categorical data. P-values are considered significant when P is less than 0.05. *Pearson’s Chi-squared test; **Kruskal–Wallis test.
Abbreviations: EFST, Elderly Fall Screening Test; 4MGS, 4-meter gait speed; UST, unipedal stance test; NVNH, non-vertebral and non-hip.
Differences in Pharmacological Therapies Among Groups in Patients Undergoing Any Treatment (n=667)
| At Low Risk of Falling | At Moderate Risk of Falling | At High Risk of Falling | ||
|---|---|---|---|---|
| Corticosteroids | 21 (6.6) | 23 (10.2) | 12 (9.7) | 0.271 |
| NSAIDs | 41 (12.9) | 42 (18.7) | 25 (20.2) | 0.077 |
| Opioids | 2 (0.6) | 3 (1.3) | 2 (1.6) | 0.550 |
| Antihypertensive drugs | 172 (54.1) | 149 (66.2) | 94 (75.8) | <0.001 |
| Anti-arrhythmics | 14 (4.4) | 20 (8.9) | 8 (6.5) | 0.107 |
| Antiplatelet agents | 54 (17.0) | 65 (28.9) | 34 (27.4) | 0.002 |
| Anticoagulants | 15 (4.7) | 16 (7.1) | 27 (21.8) | <0.001 |
| Statins | 79 (24.8) | 60 (26.7) | 26 (21.0) | 0.507 |
| Antiepileptics | 5 (1.6) | 7 (3.1) | 4 (3.2) | 0.332 |
| Antidepressants | 16 (5.0) | 19 (8.4) | 16 (12.9) | 0.017 |
| Immunosuppressants | 5 (1.6) | 2 (0.9) | 3 (2.4) | 0.530 |
| Chemotherapeutics | 1 (0.3) | 1 (0.4) | 1 (0.8) | 0.770 |
| L-thyroxine | 60 (18.9) | 40 (17.8) | 24 (19.4) | 0.922 |
| Aromatase inhibitors | 6 (1.9) | 6 (2.7) | 3 (2.4) | 0.783 |
| Anti-anxiety/sedative-hypnotics | 21 (6.6) | 25 (11.1) | 9 (7.3) | 0.167 |
| Anti-osteoporotic drugs and/or vitamin D and/or calcium supplementation | ||||
| Bisphosphonates | 72 (22.6) | 78 (34.7) | 58 (46.8) | 0.001 |
| Denosumab | 10 (3.1) | 27 (12.0) | 21 (16.9) | 0.001 |
| Teriparatide | 3 (0.9) | 5 (2.2) | 11 (8.9) | 0.001 |
| Vitamin D supplementation | 140 (44.0) | 87 (38.7) | 86 (69.4) | 0.001 |
| Calcium supplementation | 39 (12.3) | 22 (9.8) | 40 (32.3) | 0.001 |
Notes: Values are expressed as mean ± standard deviation for continuous data and counts (percentages) for categorical data. P-values are considered significant when P is less than 0.05. The Pearson’s Chi-squared test was performed.
Abbreviations: EFST, Elderly Fall Screening Test; NSAIDs, nonsteroidal anti-inflammatory drugs.